Wedbush Reaffirms Outperform Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a report released on Thursday, Benzinga reports. They presently have a $38.00 price target on the stock. Wedbush’s target price indicates a potential upside of 43.40% from the company’s current price. Other research analysts also […]

Related Keywords

Arizona ,United States ,Stifel Nicolaus ,Zentalis Pharmaceuticals ,Analyst Recommendations For Zentalis Pharmaceuticals ,Zentalis Pharmaceuticals Stock Performance ,Wells Fargo Company ,Jefferies Financial Group ,Proshare Advisors ,Zentalis Pharmaceuticals Inc ,Principal Financial Group Inc ,Securities Exchange Commission ,Us Bancorp ,News Ratings For Zentalis Pharmaceuticals Daily ,Institutional Investors Weigh In On Zentalis Pharmaceuticals ,Get Free Report ,Financial Group ,Matrix Capital Management Comp ,Exchange Commission ,State Retirement System ,Financial Advisors ,Share Advisors ,Zentalis Pharmaceuticals Daily ,Nasdaq Zntl ,Zntl ,Medical ,Reiterated Rating ,Wedbush ,